Join Our Journey
Invest for global impact
We are on a journey towards implementing break through healthcare innovation for monitoring of lungs and sinus diagnostics based on non-invasive patented laser technology.
Our goal is to significantly improve the care and life quality of preterm born infants and reduce today’s potentially harmful monitoring methods of X-ray imaging and invasive blood samples. The primary market consists of 3000 neonatal intensive care clinics in Europe and the U.S.
Antibiotic resistance is one of the top ten most important global challenges listed by the World Health Organization. 20% of all prescribed antibiotics relate to sinus infection, despite that only 2% is caused by bacteria where antibiotics can have effect. With our sinus monitoring medical device, doctors will be able to make informed decisions already at the primary care centers and thereby reduce costly and time-consuming investigations as well as decrease prescription of antibiotics. Primary markets consist of primary care centers in Europe and the U.S.